Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

Nilar Lwin, Michael Boyle, Joshua S. Davis

    Research output: Contribution to journalArticle

    Abstract

    Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

    Original languageEnglish
    Article numberofy027
    Pages (from-to)1-3
    Number of pages3
    JournalOpen Forum Infectious Diseases
    Volume5
    Issue number2
    DOIs
    Publication statusPublished - 1 Feb 2018

    Fingerprint Dive into the research topics of 'Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection'. Together they form a unique fingerprint.

  • Cite this